Senti Biosciences Holdings (SNTI) Operating Income (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Operating Income of -$18.6 million for Q4 2025, down 15.27% year-over-year from -$22.0 million in Q4 2024, and down 9.96% quarter-over-quarter from -$16.9 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Operating Income (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Operating Income history runs 5 years deep, the most recent figure standing at -$18.6 million for Q4 2025.
- In Q4 2025, Operating Income fell 15.27% year-over-year to -$18.6 million; the TTM figure through Dec 2025 stood at -$68.8 million (down 12.68% YoY), while the FY2025 annual figure was -$68.8 million, down 12.68% from the prior year.
- Operating Income for Q4 2025 stood at -$18.6 million, down from -$16.9 million in the prior quarter.
- The five-year high for Operating Income was -$1178.0 in Q1 2021, with the low at -$43.9 million in Q3 2023.
- The 5-year median for Operating Income is -$15.7 million (2024), against an average of -$15.6 million.
- The sharpest annual moves came in 2022 and 2024: Operating Income sank 998032.43% in 2022, then jumped 65.32% in 2024.
- Senti Biosciences Holdings' Operating Income stood at -$3.9 million in 2021, then tumbled by 334.42% to -$16.8 million in 2022, then decreased by 11.34% to -$18.7 million in 2023, then gained by 13.54% to -$16.2 million in 2024, then declined by 15.27% to -$18.6 million in 2025.
- Business Quant data shows SNTI's Operating Income at -$18.6 million in Q4 2025, -$16.9 million in Q3 2025, and -$16.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -14.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.64 Mn |
| Sep 30, 2025 | -16.95 Mn |
| Jun 30, 2025 | -16.80 Mn |
| Mar 31, 2025 | -16.40 Mn |
| Dec 31, 2024 | -16.17 Mn |
| Sep 30, 2024 | -15.22 Mn |
| Jun 30, 2024 | -13.36 Mn |
| Mar 31, 2024 | -16.30 Mn |
| Dec 31, 2023 | -18.70 Mn |
| Sep 30, 2023 | -43.88 Mn |
| Jun 30, 2023 | -15.19 Mn |
| Mar 31, 2023 | -14.96 Mn |
| Dec 31, 2022 | -16.79 Mn |
| Sep 30, 2022 | -14.75 Mn |
| Jun 30, 2022 | -21.77 Mn |
| Mar 31, 2022 | -11.76 Mn |
| Dec 31, 2021 | -3.87 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -9.00 Mn |
| Mar 31, 2021 | -1,178.00 |